Moderna, Inc.
200 Technology Square
Cambridge, MA
United States
Tel: 617-714-6500
Website: https://modernatx.com/
Email: careers@modernatx.com
About Moderna, Inc.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
mRNA is now a turning point in the history of science, medicine, technology, even humankind itself. With this breakthrough discovery, many of the world’s biggest and most challenging medical problems are no longer a question of “how?” but merely a question of “when?”
Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine.
Stock Symbol:
MRNA
Stock Exchange:
USNASDAQ GS
Moderna employees share their thoughts on our culture, values and mission. To hear additional employee stories and learn more about our inclusive and innovative benefits offerings, visit us on our website.
1148 articles about Moderna, Inc.
-
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
1/11/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its pipeline of innovative vaccines with three new development programs based on the clinical success of its infectious disease vaccine portfolio to date.
-
United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna
1/8/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved its mRNA vaccine against COVID-19 (COVID-19 Vaccine Moderna) for use under Regulation 174.
-
News, much of it good, keeps coming in about the efficacy of the various COVID-19 vaccines. Here’s a look.
-
Corinne Le Goff, Pharm.D. Will Join Moderna as Chief Commercial Officer on January 19
1/7/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that Corinne Le Goff, Pharm.D., MBA, will join Moderna as Chief Commercial Officer effective Tuesday, January 19, 2021.
-
European Commission Authorizes COVID-19 Vaccine Moderna in Europe
1/6/2021
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the European Commission has granted a conditional marketing authorization for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union.
-
Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel
1/5/2021
Ministry of Health of Israel has secured 6 million doses and first deliveries expected to begin in January
-
With COVID-19 still running rampant across the globe, Moderna announced it will rapidly expand its vaccine manufacturing operations in order to meet demand in the countries where the medication has received emergency authorization.
-
Moderna Provides COVID-19 Vaccine Supply Update
1/4/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided a supply update for the Moderna COVID-19 Vaccine, increasing its base-case global productio
-
Moderna to Provide Business and Pipeline Updates at the 2021 J.P. Morgan Healthcare Conference
1/4/2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at this year’s 39th annual J.P. Morgan Healthcare Conference.
-
As Operation Warp Speed struggles to ramp up vaccinations, one of the approaches under consideration is cutting the doses of the Moderna vaccine.
-
Moderna Confirms 40 Million COVID-19 Vaccine Dose Supply Agreement with the Government of the Republic of Korea
12/31/2020
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed the Company has entered into a supply agreement with the government of the Republic of Korea to provide 40 million doses of the Moderna COVID-19 Vaccine to support the government’s aim of providing vaccines to the public as soon as possible.
-
Recipharm and Moderna Finalize Agreement for Aseptic Drug Product Manufacturing and Fill-Finish for Supply to Countries Outside the U.S.
12/30/2020
Moderna, Inc. (NASDAQ:MRNA), biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a leading contract development and manufacturing organization (CDMO), today announced that they have reached an agreement to support formulation and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S.
-
Moderna Confirms Discussions With the Government of South Korea to Supply South Korea With 40 Million Doses of COVID-19 Vaccine
12/29/2020
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the Company is engaged in discussions with the government of South Korea to potentially provide 40 million or more doses of the Moderna COVID-19 Vaccine to support South Korea’s aim of providing vaccines to the public as soon as possible.
-
Moderna to Present at the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference: A View from the Top
12/29/2020
Moderna to Present at the Goldman Sachs 13 th Annual Healthcare CEOs Unscripted Conference: A View from the Top
-
The U.S. Department of Defense awarded Moderna a contract worth $1,966,598,000 for an additional 100 million doses of its COVID-19 vaccine.
-
Health Canada Authorizes Moderna COVID-19 Vaccine in Canada
12/23/2020
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Health Canada has authorized its vaccine against COVID-19 for the immunization of people 18 years of age and older under an Interim Order.
-
Health Canada authorizes Moderna COVID-19 vaccine
12/23/2020
Today, Health Canada authorized the second COVID-19 vaccine in Canada , manufactured by Moderna. Health Canada received Moderna's submission on October 12, 2020 , and after a thorough, independent review of the evidence, it has determined that the Moderna vaccine meets the Department's stringent safety, efficacy and quality requiremen
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
-
The company and Operation Warp Speed began distribution of the vaccine through McKesson, along with United Parcel Services and FedEx, over the weekend. The first vaccinations are expected today.
-
U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older
12/20/2020
Recommendation follows yesterday’s U.S. FDA authorization for emergency use of the Moderna COVID-19 Vaccine